+ Watch CORT
on My Watchlist
A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.
I'm back to add Corcept to my list of dirty dozens, stocks I've successfully rated at least 12 times without a losing score. The stock is mysteriously maintaining airtime despite weak and mostly stagnant Korlym revenues and a phase III trial for Korlym in psychotic depression that is now in its sixth year of attempting to enroll patients. I'm expecting the PI's of this trial to eventually die and leave their children to carry on the work. Meanwhile, the cash hoard is dwindling as the burn is in the double digits for the second quarter in a row. This won't end pretty, folks.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions